Careteq (ASX:CTQ) Shares Leap 38.46% as Health-Technology Stock Commands Attention

Aditi Sarkar

10 September 2026 11:17 PM AEST

Careteq (ASX:CTQ) Shares Leap 38.46% as Health-Technology Stock Commands Attention

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

CTQ shares closed 38.46% higher at $0.018 after trading between $0.013 and $0.018.
Turnover reached 10,694,900 shares, placing the company’s Market Value near $13.2 million.
Careteq Limited continues to pursue its stated operating priorities and development plans.
Investors now face execution, funding and sector-specific development risks as the company advances its plans.

Careteq Limited (ASX:CTQ) shares finished at $0.018, rising 38.46% during the session. The stock traded between $0.013 and $0.018, while 10,694,900 shares changed hands. At the closing price, the company carried an indicative Market Capitalisation of $13.2 million.

Company Business

Careteq is an Australian clinical health-technology company focused on tools that support care delivery, medication management and independent living. Its portfolio includes HMR Referrals, a software service connecting general practitioners with accredited pharmacists for Home Medicines Reviews, and Sofihub, an adaptive-care technology platform designed for monitored living environments. The company has also reshaped its operations through the sale of its Embedded Health Solutions business, concentrating attention on its retained platforms and their commercial pathways.

Sector Context

Digital health businesses operate where software, clinical workflows and regulated care services meet. Adoption can depend on evidence of usefulness, integration with existing systems, procurement cycles and the willingness of healthcare professionals or care providers to change established processes. For Careteq, the addressable setting includes primary care, pharmacy-led medication reviews, aged care and supported independent living. Recurring software Revenue can be attractive, but only when customer acquisition, retention and service costs produce sustainable unit economics.

Risks to Consider

Careteq remains a small-cap company, so Liquidity and valuation can move sharply. Commercial execution is central: slower customer onboarding, low platform use or a longer sales cycle could affect revenue timing. Healthcare privacy, cybersecurity, regulatory compliance and service reliability also matter. Investors should examine cash use, funding requirements and whether retained operations can reach sufficient scale following portfolio changes.

What to Watch Next

Future quarterly reports should clarify cash receipts, operating expenditure and progress within HMR Referrals and Sofihub. Contract wins are most informative when accompanied by deployment scope, expected timing and measurable economics. Investors can also watch customer retention, active-user trends, strategic partnerships and any further decisions about the company’s operating structure.

FAQs

Q: What was the CTQ share price?

A: CTQ closed at $0.018, representing a 38.46% increase for the session.

Q: What does Careteq Limited do?

A: Careteq is an Australian clinical health-technology company focused on tools that support care delivery, medication management and independent living.

Q: What was the trading range for CTQ?

A: The shares traded between $0.013 and $0.018, with volume of 10,694,900 shares.

Q: What should investors watch next?

A: Key areas include operational milestones, cash use, financing, regulatory progress where applicable, and evidence of commercial execution.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.